Vivani Medical(VANI)
$1.02+0.01 (+0.99%)
VANI
Vivani Medical stock drug pipeline
$1.02
At close:+0.01 (+0.99%)
Want to see VANI full AI Analyst Report?
Vivani Medical (VANI) Drug Pipeline
826 Followers
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Exenatide Implant, Bydureon Bcise (Exenatide Extended Release), Semaglutide, 1.0 Mg/Ml | Type2diabetes, Overweight And Obesity | Phase I | Completed | Assessment of Safety, Tolerability and Drug Levels of Exenatide Implant | Dec 13, 2022 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Exenatide Implant, Bydureon Bcise (Exenatide Extended Release), Semaglutide, 1.0 Mg/Ml | Phase I | Type2diabetes, Overweight And Obesity | Completed | Assessment of Safety, Tolerability and Drug Levels of Exenatide Implant | Dec 13, 2022 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Vivani Medical, Inc. (VANI) have in its pipeline
Vivani Medical VANI is currently developing the following drugs: Exenatide Implant, Bydureon Bcise (Exenatide Extended Release), Semaglutide, 1.0 Mg/Ml. These drug candidates are in various stages of clinical development as the company works toward FDA approval.

